CD4+ T Cells in Acute Versus Chronic HCV Infection

CD4 T 细胞在急性与慢性 HCV 感染中的作用

• 批准号: 9208086
• 负责人: GEORG Michael LAUER
• 金额: $ 43.5万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-02-01 至 2019-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9208086
• 关键词: Activities of Daily Living; Acute; Acute Hepatitis C; Affect; Alleles; Animals; Antigens; Antiviral Therapy; Biological; Biological Assay; Blood; CD4 Positive T Lymphocytes; CD8B1 gene; Cell Count; Cell Maintenance; Cell Survival; Cells; Characteristics; Chronic; Chronic Disease; Chronic Hepatitis C; Clinical; Data; Development; Differentiation Antigens; Epitopes; Evolution; Failure; Foundations; Future; Gene Expression Profiling; Genes; Genetic Polymorphism; Genetic Transcription; HIV; HIV Infections; Hepatitis; Hepatitis B; Hepatitis C; Hepatitis C Transmission; Hepatocyte; Human; Immune response; Immune system; Immunity; Immunologics; Immunotherapeutic agent; Immunotherapy; Impairment; Individual; Infection; Infection Control; Intervention; Knowledge; Lead; Liver; Lymphocyte; Measurable; Mediating; Modality; Modeling; Mutate; Mutation; Outcome; Pathway interactions; Pattern; Peptide Library; Peripheral Blood Mononuclear Cell; Persons; Phase; Plasma; Population; Preventive vaccine; Procedures; Production; Property; Prophylactic treatment; Recruitment Activity; Resources; Rest; Role; Sampling; Sorting - Cell Movement; Specimen; T cell response; T-Cell Activation; T-Lymphocyte; Technology; Testing; Therapeutic; Time; Translations; Vaccine Design; Vaccines; Variant; Viral; Viral Antigens; Viremia; Virus; Virus Diseases; arm; base; cohort; cytokine; design; exhaust; exhaustion; expectation; human disease; immunological intervention; intrahepatic; mouse model; programs; public health relevance; receptor; repository; response; therapy development; transcription factor; vaccine development; virtual

DESCRIPTION (provided by applicant): CD4 T cell responses are of critical importance for the control of viral infections in animals and humans. Yet surprisingly little is known about what constitutes a protective CD4 response as well as the mechanisms that lead to CD4 T cell failure. Recent technological advances in identifying and isolating virus-specific CD4 T cells and in analyzing the functional and transcriptional state of small numbers of cells now allow to answer basic questions about the role and fate of CD4 T cells in chronic versus acute infection, with the expectation that the results will enable rationale vaccine design as well as the development of targeted immunotherapeutic interventions. In order to better define critical aspects of the CD4 T cell response directly in humans, we will use the model of hepatitis C virus (HCV) infection. HCV infects almost 200 millions people worldwide and despite recent progress in antiviral therapies will remain a pressing clinical problem in the world for the foreseeable future. Thus alternative therapeutic modalities as well as prophylactic vaccines remain a high priority. Most importantly for this proposal, HCV allows to study both acute and chronic viral infection and thus protective and ineffective immunity, since an estimated 30% of infected subjects clear the virus spontaneously while the rest develop chronic infection and hepatitis. As a critical resource for our studies we have established a specimen bank with more than 30,000 PBMC and over 15,000 plasma samples from cohorts with more than 1000 HCV+ subjects, including almost 300 individuals within 6 months post infection. Based on our recent findings that virtually all subjects prime a measurable and typically multi-specific CD4 response upon HCV infection we hypothesize that functional differences between HCV-specific CD4 T cells define the outcome of HCV infection, that persistent infection gives rise to CD4 exhaustion through the activation of T cell inhibitory pathways and that the virus is able to circumvent the CD4 response by mutating towards less recognizable variants. Thus in aim 1 we will test whether CD4 responses in acute HCV infection differ in their capacity to secrete cytokines that help coordinate the different arms of the immune system and in the initiation of intracellular programs associated with T cell survival. Aim 2 will extend these studies by asking whether different functions and a different fate of the HCV-specific CD4 T cells is driven by the activatio of distinct T cell inhibitory pathways, with special consideration of intrahepatic CD4 T cells. In aim 3 we will define the role of viral escape mutations for persistence of HCV. At the end of the proposed studies we expect to have established a detailed understanding of how CD4 T cells can help to control viral infections and what differentiates protective CD4 immunity from a failed CD4 response. These results could have major implications for the prophylaxis and treatment of chronic viral infections, beyond HCV infection alone.

描述(由申请人提供)：CD4T细胞反应对于控制动物和人类的病毒感染至关重要。然而，令人惊讶的是，人们对保护性CD4应答的构成以及导致CD4T细胞衰竭的机制知之甚少。最近在鉴定和分离病毒特异性的CD4T细胞以及分析少数细胞的功能和转录状态方面的技术进步现在使人们能够回答有关CD4T细胞在慢性和急性感染中的作用和命运的基本问题，期望这些结果将使疫苗设计以及靶向免疫治疗干预措施的开发成为可能。为了更好地确定直接在人类体内的CD4T细胞反应的关键方面，我们将使用丙型肝炎病毒(HCV)感染的模型。丙型肝炎病毒感染了全世界近2亿人，尽管抗病毒疗法最近取得了进展，但在可预见的未来，仍将是世界上一个紧迫的临床问题。因此，替代治疗方式以及预防性疫苗仍然是一个高度优先事项。对于这项建议来说，最重要的是，丙型肝炎病毒允许研究急性和慢性病毒感染，从而研究保护性和无效免疫，因为估计有30%的感染者自发清除病毒，而其余的人发展为慢性感染和肝炎。作为我们研究的重要资源，我们已经建立了一个样本库，其中包括感染后6个月内的近300名患者，其中包括1000多名丙型肝炎病毒阳性受试者，其中包括30,000多名PBMC和15,000多名血浆样本。根据我们最近的发现，几乎所有的受试者都会在丙型肝炎病毒感染时启动可测量的、通常是多特异性的CD4反应，我们假设丙型肝炎病毒特异性的CD4T细胞之间的功能差异决定了丙型肝炎病毒感染的结果，持续感染通过激活T细胞抑制途径导致CD4耗尽，并且病毒能够通过突变到不太容易识别的变种来绕过CD4反应。因此，在目标1中，我们将测试急性丙型肝炎病毒感染中的CD4反应在分泌细胞因子的能力上是否不同，这些细胞因子有助于协调免疫系统的不同手臂，并启动与T细胞生存相关的细胞内程序。目的2将通过询问丙型肝炎病毒特异性CD4T细胞的不同功能和不同的命运是否由不同的T细胞抑制途径的激活驱动这些研究的扩展，特别是肝内的CD4T细胞。在目标3中，我们将定义病毒逃逸突变在丙型肝炎病毒持续存在中的作用。在拟议的研究结束时，我们希望已经建立了对CD4T细胞如何帮助控制病毒感染的详细了解，以及如何区分保护性CD4免疫和失败的CD4反应。这些结果可能对慢性病毒感染的预防和治疗具有重大意义，而不仅仅是丙型肝炎病毒感染。